abstract |
The present disclosure generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD 123 antigen (the a chain of the interleukine 3 receptor, or IL-3Ra). The present disclosure also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies. |